Summary
17.22 -0.34(-1.94%)07/02/2024
Hutchison China Meditech Ltd. (HCM)
Hutchison China Meditech Ltd. (HCM)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.94 | -3.37 | -2.88 | 2.87 | -1.66 | 45.32 | -21.48 | 27.56 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 17.22 | |
| Open | 17.34 | |
| High | 17.34 | |
| Low | 17.17 | |
| Volume | 60,618 | |
| Change | -0.34 | |
| Change % | -1.94 | |
| Avg Volume (20 Days) | 76,196 | |
| Volume/Avg Volume (20 Days) Ratio | 0.80 | |
| 52 Week Range | 11.60 - 21.92 | |
| Price vs 52 Week High | -21.44% | |
| Price vs 52 Week Low | 48.45% | |
| Range | -0.69 | |
| Gap Up/Down | -0.46 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,001 | |
| EBIDTA | -106,662,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 46.21 | |
| Book Value | 5.8600 | |
| Earnings Per Share | -1.2400 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | -1.2400 | |
| Revenues | ||
| Profit Marging | -0.6405 | |
| Operating Marging (TTM) | -0.9414 | |
| Return on asset (TTM) | -0.1823 | |
| Return on equity (TTM) | -0.2413 | |
| Revenue TTM | 278,572,992 | |
| Revenue per share TTM | 1.9350 | |
| Quarterly Revenue Growth (YOY) | 0.3730 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -135,319,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.8216 | |
| Revenue Enterprise Value | 17.8284 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 172,892,000 | |
| Shares Float | 85,427,198 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.41 | |
| Institutions (%) | 33.73 | |
06/26 04:30 EST - globenewswire.com
HUTCHMED to Announce 2024 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED to Announce 2024 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
06/25 10:54 EST - businesswire.com
HCM Digital World Class Matrix™ Identifies Software Innovations and Leading Providers
MIAMI--(BUSINESS WIRE)--The Hackett Group, Inc. (NASDAQ: HCKT), released its first Digital World Class Matrix™ focused on the human capital management (HCM) software market – a growing segment of the human resources (HR) technology landscape – driven by technology innovation and increasing HR demands. Optimizing HR processes and predictively analyzing workforce trends are critical to the successful operation of businesses of all sizes. While the “great resignation” is over, employee engagement.
HCM Digital World Class Matrix™ Identifies Software Innovations and Leading Providers
MIAMI--(BUSINESS WIRE)--The Hackett Group, Inc. (NASDAQ: HCKT), released its first Digital World Class Matrix™ focused on the human capital management (HCM) software market – a growing segment of the human resources (HR) technology landscape – driven by technology innovation and increasing HR demands. Optimizing HR processes and predictively analyzing workforce trends are critical to the successful operation of businesses of all sizes. While the “great resignation” is over, employee engagement.
06/24 05:30 EST - globenewswire.com
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —
06/21 16:00 EST - globenewswire.com
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
06/16 20:00 EST - globenewswire.com
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA 1 exposure — — Data supported regulatory submission in China accepted in January 2024 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J.
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA 1 exposure — — Data supported regulatory submission in China accepted in January 2024 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J.
06/06 20:00 EST - globenewswire.com
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31, 2024.
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological malignancies in China. The first patient received their first dose on May 31, 2024.
06/02 20:00 EST - globenewswire.com
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024
05/23 20:00 EST - globenewswire.com
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online.
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online.
05/20 22:34 EST - seekingalpha.com
Paycom: Initiating Buy On Strong Growth Tailwind And BETI Pricing Power
Paycom is recommended as a buy due to its long-term growth potential and strong value proposition with its BETI product. The global HCM software industry is expected to grow, providing opportunities for cloud-based HCM solutions like PAYC. The revised sales strategy and international expansion are expected to drive customer satisfaction and future growth for PAYC.
Paycom: Initiating Buy On Strong Growth Tailwind And BETI Pricing Power
Paycom is recommended as a buy due to its long-term growth potential and strong value proposition with its BETI product. The global HCM software industry is expected to grow, providing opportunities for cloud-based HCM solutions like PAYC. The revised sales strategy and international expansion are expected to drive customer satisfaction and future growth for PAYC.
05/20 11:11 EST - https://www.businesswire.com
Applications Software Technology收购Symatrix，以加速甲骨文云服务的全球扩张
伊利诺伊州莱尔--(BUSINESS WIRE)--(美国商业资讯)-- 领先的数字化转型解决方案供应商Applications Software Technology (AST) 今天宣布签订收购英国领先IT和甲骨文服务供应商Symatrix的最终协议。此次收购是AST全球扩张的重要一步。 AST首席执行官Justin Winter表示：“Symatrix的加入补充并拓宽了AST的核心服务，使我们能够进入新的全球市场。通过合作，我们将能够为合而为一的客户群提供更优质的服务。我们将继续提供高价值的解决方案，为全球客户带来可量化的价值和成果。” Symatrix在英国的成熟的客户群加强了AST在众多行业中的垂直专长，并为进一步拓展新兴产业提供了平台。Symatrix深厚的咨询能力还将拓展AST在甲骨文云应用方面的能力，包括供应链管理和人力资本管理。 Symatrix首席执行官Chris Brooks表示：”AST是一流的企业解决方案提供商，也是能够满足公共和商业行业复杂云需求的高端咨询公司。与AST的强强联手是Symatrix的自然发展过程，让我们能够以更多的资源和技术为客户提供服务。” Recognize管理合伙人、AST董事会主席、甲骨文前总裁Charles Phillips补充道：“AST和Symatrix是甲骨文云服务领域的强强联手，互补的终端市场有助于巩固双方在两大洲的领导地位。” 过渡期结束后，Chris和领导团队将继续留任，并重新专注于通过AST新的产品套件和交付区域扩大英国客户群。 Winter表示：“AST全面倡导包容和创新文化，Symatrix也体现了这些价值观，我们的合作将为客户和员工开辟一个充满无限可能的世界。” 关于Applications Software Technology (AST) LLC AST是屡获殊荣的全方位企业服务解决方案供应商，二十多年来为政府和商业部门的客户提供数字化转型指导。AST通过软件解决方案、流程工程和管理改革帮助客户实现组织转型，并提升领导力。从云技术到传统的本地应用程序部署，AST的服务涵盖SaaS、PaaS和IaaS的各个方面。AST还提供灵活的托管服务，以满足全球200多家客户的需求。如需了解更多信息，请访问www.astcorporation.com。 关于Symatrix Symatrix是一家总部位于英国的甲骨文人力资本管理（HCM）、企业资源计划（ERP）和供应链管理（SCM）云咨询、应用管理及外包薪资管理供应商。Symatrix与公共部门和商业客户合作，以创新方式帮助客户释放甲骨文云的无限可能。 免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
Applications Software Technology收购Symatrix，以加速甲骨文云服务的全球扩张
伊利诺伊州莱尔--(BUSINESS WIRE)--(美国商业资讯)-- 领先的数字化转型解决方案供应商Applications Software Technology (AST) 今天宣布签订收购英国领先IT和甲骨文服务供应商Symatrix的最终协议。此次收购是AST全球扩张的重要一步。 AST首席执行官Justin Winter表示：“Symatrix的加入补充并拓宽了AST的核心服务，使我们能够进入新的全球市场。通过合作，我们将能够为合而为一的客户群提供更优质的服务。我们将继续提供高价值的解决方案，为全球客户带来可量化的价值和成果。” Symatrix在英国的成熟的客户群加强了AST在众多行业中的垂直专长，并为进一步拓展新兴产业提供了平台。Symatrix深厚的咨询能力还将拓展AST在甲骨文云应用方面的能力，包括供应链管理和人力资本管理。 Symatrix首席执行官Chris Brooks表示：”AST是一流的企业解决方案提供商，也是能够满足公共和商业行业复杂云需求的高端咨询公司。与AST的强强联手是Symatrix的自然发展过程，让我们能够以更多的资源和技术为客户提供服务。” Recognize管理合伙人、AST董事会主席、甲骨文前总裁Charles Phillips补充道：“AST和Symatrix是甲骨文云服务领域的强强联手，互补的终端市场有助于巩固双方在两大洲的领导地位。” 过渡期结束后，Chris和领导团队将继续留任，并重新专注于通过AST新的产品套件和交付区域扩大英国客户群。 Winter表示：“AST全面倡导包容和创新文化，Symatrix也体现了这些价值观，我们的合作将为客户和员工开辟一个充满无限可能的世界。” 关于Applications Software Technology (AST) LLC AST是屡获殊荣的全方位企业服务解决方案供应商，二十多年来为政府和商业部门的客户提供数字化转型指导。AST通过软件解决方案、流程工程和管理改革帮助客户实现组织转型，并提升领导力。从云技术到传统的本地应用程序部署，AST的服务涵盖SaaS、PaaS和IaaS的各个方面。AST还提供灵活的托管服务，以满足全球200多家客户的需求。如需了解更多信息，请访问www.astcorporation.com。 关于Symatrix Symatrix是一家总部位于英国的甲骨文人力资本管理（HCM）、企业资源计划（ERP）和供应链管理（SCM）云咨询、应用管理及外包薪资管理供应商。Symatrix与公共部门和商业客户合作，以创新方式帮助客户释放甲骨文云的无限可能。 免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
05/20 11:08 EST - https://www.businesswire.com
Applications Software Technology adquiere Symatrix con el objetivo de acelerar su expansión global en servicios de Oracle Cloud
LISLE, Ill.--(BUSINESS WIRE)--Applications Software Technology (AST), proveedor líder de soluciones para la transformación digital, anuncia que ha firmado un acuerdo definitivo para la adquisición de Symatrix, el proveedor de servicios de TI y Oracle. La adquisición de Symatrix, el principal proveedor de estos servicios en el Reino Unido, es un paso significativo en la expansión global de AST. "Las capacidades de Symatrix complementan y amplían los servicios básicos de AST y nos permiten llegar a nuevos mercados globales", declaró Justin Winter, director ejecutivo de AST. "Si trabajamos juntos podremos ofrecer mejores servicios a nuestra base combinada de clientes. Seguiremos ofreciendo soluciones de alto valor que proporcionen valor y resultados medibles a nuestros clientes a escala global". Symatrix aporta una cartera de clientes establecida en el Reino Unido que refuerza la experiencia vertical de AST en numerosas industrias y proporciona una plataforma para seguir expandiéndose en sectores emergentes. Las extraordinarias capacidades de consultoría de Symatrix también ampliarán las capacidades de AST a través de aplicaciones de Oracle Cloud, lo que incluye gestión de la cadena de suministro y de capital humano. "AST es un proveedor de soluciones empresariales de primer nivel que se ha convertido en una consultora de referencia para necesidades complejas en la nube para todos los sectores públicos y comerciales", señaló Chris Brooks, director ejecutivo de Symatrix. "Unir fuerzas con AST es una progresión natural para Symatrix y nos permite prestar servicio a nuestros clientes con recursos y servicios técnicos aún mayores". "AST y Symatrix representan una combinación poderosa en cuanto a servicios de Oracle Cloud", añadió Charles Phillips, socio director de Recognize, presidente del Consejo de AST y expresidente de Oracle. "La exposición complementaria al mercado final ayuda a consolidar las posiciones de liderazgo de las empresas en dos continentes". Una vez completada la transición, Chris y el equipo directivo permanecerán en sus puestos con un enfoque renovado y orientado a la expansión de la base de clientes del Reino Unido, con un nuevo conjunto de ofertas y geografías de entrega de AST. "En AST, fomentamos una cultura de inclusión e innovación en todos los niveles de nuestra organización", comentó Winter. "La familia Symatrix encarna estos valores, y nuestra asociación abre un mundo de posibilidades apasionantes, tanto para los clientes como para los empleados". Acerca de Applications Software Technology (AST) LLC AST es un proveedor de soluciones empresariales de servicio completo, ganador de numerosos premios, que ha guiado la transformación digital de clientes de los sectores gubernamental y comercial durante más de dos décadas. Los que los clientes buscan en AST es liderazgo y asistencia en la transformación de sus organizaciones a través de soluciones de software, ingeniería de procesos y gestión del cambio. Desde tecnología en la nube hasta aplicaciones locales heredadas, los servicios de AST abarcan todos los aspectos de SaaS, PaaS e IaaS. AST también ofrece servicios gestionados flexibles, que satisfacen las necesidades de más de 200 clientes en todo el mundo. Para obtener más información, visite www.astcorporation.com. Acerca de Symatrix Symatrix es un proveedor de consultoría en la nube, gestión de aplicaciones y externalización de nóminas de Oracle HCM (gestión del capital humano), ERP (planificación de recursos empresariales) y SCM (gestión de la cadena de suministro) con sede en el Reino Unido. Symatrix trabaja con clientes del sector público y comercial para ayudarles con innovación a aprovechar las infinitas y emocionantes posibilidades de Oracle Cloud. El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.
Applications Software Technology adquiere Symatrix con el objetivo de acelerar su expansión global en servicios de Oracle Cloud
LISLE, Ill.--(BUSINESS WIRE)--Applications Software Technology (AST), proveedor líder de soluciones para la transformación digital, anuncia que ha firmado un acuerdo definitivo para la adquisición de Symatrix, el proveedor de servicios de TI y Oracle. La adquisición de Symatrix, el principal proveedor de estos servicios en el Reino Unido, es un paso significativo en la expansión global de AST. "Las capacidades de Symatrix complementan y amplían los servicios básicos de AST y nos permiten llegar a nuevos mercados globales", declaró Justin Winter, director ejecutivo de AST. "Si trabajamos juntos podremos ofrecer mejores servicios a nuestra base combinada de clientes. Seguiremos ofreciendo soluciones de alto valor que proporcionen valor y resultados medibles a nuestros clientes a escala global". Symatrix aporta una cartera de clientes establecida en el Reino Unido que refuerza la experiencia vertical de AST en numerosas industrias y proporciona una plataforma para seguir expandiéndose en sectores emergentes. Las extraordinarias capacidades de consultoría de Symatrix también ampliarán las capacidades de AST a través de aplicaciones de Oracle Cloud, lo que incluye gestión de la cadena de suministro y de capital humano. "AST es un proveedor de soluciones empresariales de primer nivel que se ha convertido en una consultora de referencia para necesidades complejas en la nube para todos los sectores públicos y comerciales", señaló Chris Brooks, director ejecutivo de Symatrix. "Unir fuerzas con AST es una progresión natural para Symatrix y nos permite prestar servicio a nuestros clientes con recursos y servicios técnicos aún mayores". "AST y Symatrix representan una combinación poderosa en cuanto a servicios de Oracle Cloud", añadió Charles Phillips, socio director de Recognize, presidente del Consejo de AST y expresidente de Oracle. "La exposición complementaria al mercado final ayuda a consolidar las posiciones de liderazgo de las empresas en dos continentes". Una vez completada la transición, Chris y el equipo directivo permanecerán en sus puestos con un enfoque renovado y orientado a la expansión de la base de clientes del Reino Unido, con un nuevo conjunto de ofertas y geografías de entrega de AST. "En AST, fomentamos una cultura de inclusión e innovación en todos los niveles de nuestra organización", comentó Winter. "La familia Symatrix encarna estos valores, y nuestra asociación abre un mundo de posibilidades apasionantes, tanto para los clientes como para los empleados". Acerca de Applications Software Technology (AST) LLC AST es un proveedor de soluciones empresariales de servicio completo, ganador de numerosos premios, que ha guiado la transformación digital de clientes de los sectores gubernamental y comercial durante más de dos décadas. Los que los clientes buscan en AST es liderazgo y asistencia en la transformación de sus organizaciones a través de soluciones de software, ingeniería de procesos y gestión del cambio. Desde tecnología en la nube hasta aplicaciones locales heredadas, los servicios de AST abarcan todos los aspectos de SaaS, PaaS e IaaS. AST también ofrece servicios gestionados flexibles, que satisfacen las necesidades de más de 200 clientes en todo el mundo. Para obtener más información, visite www.astcorporation.com. Acerca de Symatrix Symatrix es un proveedor de consultoría en la nube, gestión de aplicaciones y externalización de nóminas de Oracle HCM (gestión del capital humano), ERP (planificación de recursos empresariales) y SCM (gestión de la cadena de suministro) con sede en el Reino Unido. Symatrix trabaja con clientes del sector público y comercial para ayudarles con innovación a aprovechar las infinitas y emocionantes posibilidades de Oracle Cloud. El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.
05/17 10:00 EST - globenewswire.com
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-
05/16 20:00 EST - globenewswire.com
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
05/13 20:00 EST - globenewswire.com
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase (“IDH”) 1 or 2 relapsed / refractory acute myeloid leukemia (“AML”) in China. The first patient received their first dose on May 11, 2024.
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase (“IDH”) 1 or 2 relapsed / refractory acute myeloid leukemia (“AML”) in China. The first patient received their first dose on May 11, 2024.
05/13 20:00 EST - globenewswire.com
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib and anti-PD-1 activity with Hengrui's camrelizumab, promoting the immune response against tumor cells — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phase II/III trial to evaluate the efficacy of a combination of the HUTCHMED drug candidate surufatinib, the Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui Pharma”) PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (“PDAC”) in China.
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib and anti-PD-1 activity with Hengrui's camrelizumab, promoting the immune response against tumor cells — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phase II/III trial to evaluate the efficacy of a combination of the HUTCHMED drug candidate surufatinib, the Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui Pharma”) PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (“PDAC”) in China.
05/08 04:30 EST - globenewswire.com
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024.
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024.
04/30 13:00 EST - zacks.com
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
04/30 10:56 EST - zacks.com
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
The mean of analysts' price targets for HUTCHMED (HCM) points to a 38.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
The mean of analysts' price targets for HUTCHMED (HCM) points to a 38.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
04/26 08:30 EST - globenewswire.com
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
04/05 04:30 EST - globenewswire.com
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.